Explore Exclusive ADC Content

NEW! Speaker Interviews

Click below to access the full interview with Ting Xu, Chief Executive Officer at Alphamab Oncology, who will be speaking for the first time at the event.

As the ADC landscape continues to grow, why is differentiation more important than ever in 2025?

The therapeutic landscape is getting overcrowded … raising questions on whether meaningful differences will be generated between conjugates targeting low or mid-level expression tumor antigens. We believe differentiation in next-generation ADCs will come from:

  1. Leveraging the function of the antibody, particularly bispecific ADCs
  2. Identifying novel and better payload mechanisms
  3. Developing multi-payload ADCs with suitable linkers
  4. Further increasing tumor-specific release of payloads

Click below to access the full interview with Hong Wan, Chief Executive Officer at Tallac Therapeutics, the first company to enter the clinic with an AOC for oncology.

What is your current ADC focus and what insights you will share at World ADC San Diego 2025?

“Our most advanced program, TAC-001, has demonstrated expected immune activation, single-agent activity including complete response, and a generally well-tolerated safety profile in a Phase 1 study with solid tumor patients. At the meeting, we will be presenting data on our novel payload development as well as preclinical and clinical results from our TAC-001 and other programs.

I’m excited to attend to exchange ideas, learn from each other, and help to support each other’s work towards the common goal of making better medicines for cancer patients.”

busy conference room
Explore the Agenda

Hear the latest industry insights and discover cutting-edge, end-to-end ADC content from early discovery to late-stage manufacturing.

networking at booth
Partner With Us

Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.

audience asking question
Join Biopharma Experts

Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.